BCRX Q1 2020 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-18.1% YoY

Gross Profit

$5M98.6% margin

Operating Income

-$41M-849.6% margin

Net Income

-$38M-779.6% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

-87.9%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$137M

Total Liabilities

$133M

Stockholders' Equity

$4M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$6M	-18.1%
Gross Profit	$5M	$4M	+8.0%
Operating Income	-$41M	-$29M	-39.7%
Net Income	-$38M	-$31M	-21.1%

Revenue Segments

Collaborative and Other Research and Development

$3M55%

Royalty

$2M40%

Product

$218,0005%